Application of nucleotide analogs in the preparation of drugs for the prevention and / or treatment of diseases caused by bovine nodular dermatosis virus
By using nucleotide analogs such as idoxuridine, non-aluridine, cytarabine, and vidarabine as active ingredients, the drug addresses the lack of effective treatments for bovine nodular dermatovirus (LSDV) in existing technologies, achieving effective inhibition and treatment of LSDV.
Patent Information
- Application Number
- CN202510415320.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-03
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-04-03
AI Technical Summary
There is a lack of effective drugs in the current technology for the prevention and treatment of diseases caused by bovine nodular dermatitis virus (LSDV), especially due to the side effects of attenuated live vaccine vaccination and the risk of recombinant strains, there is an urgent need to develop new antiviral drugs.
Nucleotide analogs idoxuridine, non-aluridine, cytarabine, and vidarabine are used as active ingredients to prepare drugs that inhibit the replication of bovine nodular dermatosis virus, at concentrations of 20 μM, 5 μM, 0.5 μM, and 20 μM, respectively. Dosage forms include tablets, capsules, oral liquids, granules, pills, or injections.
These nucleotide analogs showed significant inhibitory activity against LSDV proliferation in MDBK and Vero cell lines, with a wide safety margin and good antiviral efficacy, providing new drug options for the prevention and treatment of bovine nodular dermatosis virus disease.
Smart Images

Figure CN120131692B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of veterinary drug technology, and specifically relates to a new use of a class of monomeric compounds, particularly the use of nucleotide analogs in the preparation of drugs for the prevention and / or treatment of diseases caused by bovine nodular dermatosis virus. Background Technology
[0002] Bovine lumpy skin disease (LSD) is a subacute to acute infectious disease caused by bovine lumpyskin disease virus (LSDV), characterized by nodular lesions on the skin of cattle. LSDV belongs to the Poxviridae family (…). Poxviridae ), Goatpoxvirus genus ( Capripoxvirus The mortality rate of cattle infected with LSDV is approximately 10%, and the morbidity rate is about 90%. Affected cattle exhibit symptoms such as fever, emaciation, decreased milk production, and nodules all over the body, severely limiting the economic benefits of cattle farming. Current technologies mainly employ a strategy and measures combining emergency immunization with attenuated live vaccines and isolation and culling for LSD control. Although vaccination currently has good protective effects, clinical results show that attenuated live vaccines have certain side effects, and increasing research demonstrates the risk of strain recombination when using live attenuated vaccines. Currently, there are no effective drugs for the treatment of LSDV. Given the limitations of vaccine immunization, there is an urgent need to develop effective drugs for the prevention or treatment of LSD as a technological reserve. Summary of the Invention
[0003] In view of the shortcomings of the prior art, the present invention provides the application of nucleotide analogs in the preparation of drugs for the prevention and / or treatment of diseases caused by bovine nodular dermatosis virus, which is expected to bring a new antiviral drug for the prevention and treatment of LSD.
[0004] The technical solution provided by this invention is as follows:
[0005] This invention provides the use of nucleotide analogs in the preparation of medicaments for the prevention and / or treatment of diseases caused by bovine nodular dermatosis virus, wherein the nucleotide analogs are selected from any one or more of idoxuridine, non-irauratenic acid, cytarabine, and vidarabine.
[0006] Furthermore, the disease caused by the bovine nodular dermatitis virus is bovine nodular dermatitis caused by the bovine nodular dermatitis virus.
[0007] Furthermore, the drug uses one or more of idoxuridine, non-aluridine, cytarabine, and vidarabine as its active ingredient.
[0008] Furthermore, the concentration of idoxuridine used in the drug is 20 μM, the concentration of non-aluridine is 5 μM, the concentration of cytarabine is 0.5 μM, and the concentration of vidarabine is 20 μM.
[0009] Furthermore, the drug is a drug that inhibits the replication phase of bovine nodular dermatitis virus.
[0010] This invention also provides the use of nucleotide analogs in any one of the following (1)-(3), (1) To prepare drugs for the prevention and / or treatment of bovine nodular dermatitis virus infection; (2) Preparation of bovine nodular dermatitis virus inhibitor; (3) Preparation of drugs to inhibit the proliferation of bovine nodular dermatitis virus; The nucleotide analogue is selected from any one or more of iodoside, non-iodoside, cytarabine, and vidarabine.
[0011] The present invention also provides a medicament for treating bovine nodular dermatitis, wherein the medicament has an effective amount of the aforementioned nucleotide analogue as its active ingredient.
[0012] Furthermore, the drug also includes one or more pharmaceutically acceptable carriers.
[0013] Furthermore, the pharmaceutically acceptable carrier includes: excipients, fillers, binders, wetting agents, disintegrants, diluents, and / or surfactants.
[0014] Furthermore, the dosage form of the drug is any one or more of tablets, capsules, oral liquids, granules, pills, or injections.
[0015] Beneficial effects
[0016] This invention is the first to discover that idoxuridine, non-aluridine, cytarabine, and vidarabine can inhibit the proliferation of bovine nodular dermatitis virus (LSDV) and can be used to treat diseases caused by LSDV infection. In the MDBK and Vero cell lines, the selectivity index (SI) for idoxuridine as an LSDV drug was greater than 62.11 and 7.89, respectively; the SI for non-aluridine as an LSDV drug was greater than 303.03 and 31.55, respectively; the SI for cytarabine as an LSDV drug was greater than 714.29 and 2000, respectively; and the SI for vidarabine as an LSDV drug was greater than 30.12 and 14.71, respectively. This indicates that idoxuridine, non-aluridine, cytarabine, and vidarabine have a wide safety margin in inhibiting LSDV proliferation. Therefore, idoxuridine, non-aluridine, cytarabine, and vidarabine show good promise in the preparation of anti-bovine nodular dermatitis virus drugs. Attached Figure Description
[0017] Figure 1 This is a schematic diagram of the chemical structure of the compound;
[0018] Figure 2 These are the activity curves and cytotoxicity curves of the compound in MDBK for inhibiting LSDV proliferation;
[0019] Figure 3 These are the activity curves and cytotoxicity curves of the compound in Vero against LSDV proliferation;
[0020] Figure 4 The fluorescence images show the inhibition of rLSDV proliferation in MDBK by different concentrations of the compound;
[0021] Figure 5 These are fluorescence images showing the inhibition of rLSDV proliferation by different concentrations of the compound in Vero;
[0022] Figure 6 Through TCID 50 The inhibitory effects of the compounds on LSDV were detected (Note: iodoside 20 μM, non-iodoside 5 μM, cytarabine 0.5 μM and vidarabine 20 μM).
[0023] Figure 7 The inhibitory effect of the compounds on LSDV was detected by qPCR (Note: iodoside 20 μM, non-iodoside 5 μM, cytarabine 0.5 μM and vidarabine 20 μM).
[0024] Figure 8 The inhibitory effects of the compounds on LSDV at different MOIs were detected by Western blot (Note: iodoside 20 μM, non-iodoside 5 μM, cytarabine 0.5 μM and vidarabine 20 μM).
[0025] Figure 9 This is a diagram of the Time of Addition experimental design.
[0026] Figure 10 The inhibitory effects of mCherry-labeled compounds on rLSDV at different stages were measured (Note: iodoside 20 μM, non-iodoside 5 μM, cytarabine 0.5 μM and vidarabine 20 μM).
[0027] Figure 11 The inhibitory effects of the compounds on rLSDV at different stages were analyzed using Luciferase (Note: iodoside 20 μM, non-iodoside 5 μM, cytarabine 0.5 μM and vidarabine 20 μM).
[0028] Figure 12The compounds inhibit LSDV DNA synthesis (Note: iodoside 20 μM, non-iodoside 5 μM, cytarabine 0.5 μM and vidarabine 20 μM). Detailed Implementation
[0029] This invention provides the use of nucleotide analogs in the preparation of medicaments for the prevention and / or treatment of diseases caused by bovine nodular dermatosis virus; wherein the nucleotide analogs are selected from any one or more of idoxuridine, non-irauratenic acid, cytarabine, and vidarabine.
[0030] It should be noted that idoxuridine, fialuridine, cytarabine, and vidarabine are all monomeric compounds, belonging to the nucleotide analogue family. The CAS number for fialuridine is 69123-98-4, and its chemical formula is C9H10FIN2O5; the CAS number for idoxuridine is 54-42-2, and its chemical formula is C9H11IN2O5; the CAS number for cytarabine is 147-94-4, and its chemical formula is C9H13N3O5; and the CAS number for vidarabine is 5536-17-4, and its chemical formula is C10H13N5O4. The chemical structural formulas of the four compounds are as follows: Figure 1 As shown.
[0031] Example 1
[0032] 1. Experimental Materials and Methods
[0033] 1.1 Experimental Materials
[0034] Iodidine, non-aluridine, cytarabine, and vidarabine were purchased from MCE. RIPA protein lysis buffer was purchased from Yuanye Company. DNA extraction kit, CCK-8 kit, reverse transcription reagent, and SYBR Green Master Mix were purchased from YEASEN. β-Tublin mouse monoclonal antibody, HRP-labeled goat anti-rabbit secondary antibody, and HRP-labeled goat anti-mouse secondary antibody were purchased from Yaxin Company. Trypsin was purchased from Solarbio. LSDV rabbit polyclonal antibody was prepared and preserved in our laboratory. Alexa Fluor™ 594-labeled goat anti-rabbit secondary antibody was purchased from Thermo Fisher Scientific. BeyoClick™ EdU-488 cell proliferation assay kit and BeyoClick™ EU-488 RNA synthesis assay kit were purchased from Beyotime International Co., Ltd. MDBK, Vero cell line, fetal bovine serum, and DMEM were purchased from Nanjing Senbeijia Co., Ltd. LSDV rabbit polyclonal antibody was prepared and preserved in our laboratory. The preparation method for LSDV rabbit polyclonal antibody is as follows:
[0035] LSDV virus was mixed with Freund's complete adjuvant at a 1:1 ratio, emulsified, and used as an immunogen. The concentration was 0.5 × 10⁻⁶.6.2 TCID 50 New Zealand white rabbits were immunized by subcutaneous injection at multiple sites with the prescribed dose; subsequently, booster immunizations were administered every 14 days with the same dose of Freund's incomplete adjuvant, for a total of 3 immunizations; serum was collected 14 days after the 3rd immunization and stored at -20 ℃.
[0036] The LSDV XJ201901 strain was isolated, identified, and deposited by the China Animal Health and Epidemiology Center, with NCBI GeneBank accession number OM984485. The specific preparation method for the recombinant rLSDV strain carrying the mCherry and Luciferase expression cassette is as follows:
[0037] LSDV's ORF50 and ORF51 are two adjacent proteins. According to literature reports, inserting a foreign gene between the genes encoding these two proteins does not affect viral replication. Therefore, we used this region as the insertion site for the mCherry and firefly luciferase reporter genes (Luciferase). First, donor plasmids carrying mCherry and Luciferase were constructed. During recombinant virus construction, the MDBK cell line was infected with the LSDV XJ201901 strain. Six hours later, the donor plasmid was transfected into the MDBK cell line. At this time, the viral DNA was recombined by intracellular homologous recombination enzymes according to the homologous sequence of the donor plasmid, thus recombining the DNA fragment corresponding to the donor plasmid into the viral genome's ORF50 and ORF51 gene positions. Then, the recombinant strain emitting red fluorescence was purified through three consecutive rounds of plaque assays, finally obtaining the rLSDV strain simultaneously expressing mCherry and Luciferase for subsequent experiments. The donor plasmid sequence is as follows:
[0038]
[0039] 1.2 Drug CC 50 Detection
[0040] Inoculate 2×10⁶ cells into 96-well plates 4 MDBK or Vero cell suspension (100 μL / well). Pre-culture the plate in an incubator for 24 h (37℃, 5% CO2). Perform 3-fold serial dilutions of the drug with cell maintenance medium, creating 8 dilutions (maximum drug concentration 100 μM). Treat cells with each diluted drug solution for 72 h, with an equal volume of DMSO as a control for each concentration. Add 10 μL of CCK-8 solution to each well, avoiding bubble formation. Incubate the plate in an incubator for 2 h. Measure the absorbance at 450 nm using a microplate reader. Calculate cell viability using the following formula: Cell viability = [OD (drug-treated group) - OD (blank group)] / [OD (control group) - OD (blank group)] × 100%. Experimental group: OD values of wells containing cells, CCK-8 solution, and drug solution. Blank group: OD values of wells containing maintenance medium and CCK-8 solution but without cells. Control group: OD values of wells containing cells, CCK-8 solution, and DMSO solution. Finally, GraphPad was used to draw the CC of the drug. 50 curve.
[0041] 1.3 Drug IC 50 Detection
[0042] Inoculate 2×10⁶ cells into 96-well plates 4 MDBK or Vero cell suspension (100 μL / well). Incubate the culture plates in an incubator for 20 h. Perform 3-fold serial dilutions of the drug with cell maintenance medium to obtain drug dilutions, for a total of 8 dilutions (maximum drug concentration 100 μM). Take 30 μL of the drug dilution and add [amount missing] TCID45 solution with a Multiplicity of Infection (MOI) of 0.01 (200 TCID45). 50 MOI = TCID at the time of infection 50 The rLSDV virus solution (volume / cell count) was diluted to obtain a drug-virus mixture. The cell culture medium was then discarded, and 30 μL of the incubated drug-virus mixture was added. The cells were incubated at 37 °C for 2 h. The drug-virus mixture was then discarded, and the cells were carefully washed once with PBS. 200 μL of drug dilution was added to each well, and the cells were cultured for another 72 h. An equal volume of DMSO was used as a control group, and an untreated control group was also established. Cell luminescence was recorded under a fluorescence microscope. The cell culture medium was then aspirated, and 100 μL of cell lysis buffer was added to each well. The cells were incubated on ice for 5 min to fully lyse the cells.
[0043] Add 20 μL of lysis buffer to a black ELISA plate. Dilute the firefly luciferase substrate (50×) and kidney luciferase substrate (50×) to 1× working solution with their respective buffers. Incubate at room temperature. Add 100 μL of firefly luciferase reaction solution to each well, shake to mix, and immediately detect the activity of firefly luciferase (within 30 min). Calculate the data using the following formula: Inhibition rate = 1 - (Experimental group value / Control group value) × 100%. Wherein, blank group: untreated cells from the same batch as the experimental group. Experimental group: cells treated with a mixture of drug and virus. Control group: cells treated with a mixture of DMSO and virus. Experimental group value = Experimental group reading - Blank group reading. Control group value = Control group reading - Blank group reading. Finally, use GraphPad to plot the IC50 of the drug. 50 curve.
[0044] 1.4 Western blot experiment
[0045] Inoculate 1×10⁻⁶ cells into 24-well plates 5 MDBK or Vero cell suspension (500 μL / well). Incubate the culture plates in an incubator for 20 h. Then discard the cell culture medium and add 200 μL of 0.01 MOI (1000 TCID50) to each well. 50 ) and 0.1 MOI (10000 TCID) 50LSDV and the drug maintenance medium were incubated at 37 °C for 2 h. The liquid was then discarded, and the cells were carefully washed once with PBS. 1000 μL of the drug-containing maintenance medium was added to the wells, and the cells were cultured for another 72 h. The cell culture medium in the culture dish was discarded, and the cells were washed twice with pre-chilled 1×PBS. RIPA lysis buffer was added, and the cells were lysed on ice for 10 min. The lysed mixture was transferred to a 1.5 mL EP tube and centrifuged at 12000 g for 10 min at 4 °C. 80 μL of the supernatant was collected, and 20 μL of 5× Loading Buffer was added. After mixing, the mixture was heated at 95 °C for 5 min, followed by brief centrifugation before sample loading and analysis. An equal volume of the sample was added to a PAGE gel for SDS-PAGE electrophoresis at a constant voltage of 80 V. When the bromophenol blue migrated to the bottom of the gel, the cells were transferred using a semi-dry transfer apparatus, and the transfer filter paper was soaked in pre-chilled transfer buffer. Place the following layers in the order from bottom to top: filter paper, NC membrane, gel, and filter paper, taking care to remove air bubbles. The program is: constant current 0.3 A, voltage limit 25 V, time 33 min. After completion, block with TBST containing 5% skim milk at room temperature for 2 h. After blocking, wash three times with TBST at room temperature for 5 min each time, add rabbit anti-LSDV polyclonal antibody and mouse anti-β-Tubulin monoclonal antibody, and incubate at 4 ℃ for 12 h. Wash three times with TBST for 5 min each time, add the corresponding HRP-labeled goat anti-rabbit and goat anti-mouse secondary antibodies, and incubate at room temperature for 1 h. Wash three times with TBST for 5 min each time, and finally treat with ECL chemiluminescence solution before exposure in an exposure apparatus.
[0046] 1.5 qPCR experiment
[0047] Sample preparation: Inoculate 1×10⁶ samples into a 24-well plate. 5 MDBK cell suspension (500 μL / well). Culture plates were incubated for 20 h. Then, the cell culture medium was discarded, and 200 μL of MDBK cell suspension containing 0.01 MOI (1000 TCID50) was added to each well. 50 LSDV and the drug maintenance medium were incubated at 37 °C for 2 h. The liquid was then discarded, and the cells were carefully washed once with PBS. 1000 μL of the drug-containing maintenance medium was added to the wells, and the cells were cultured for another 72 h.
[0048] DNA Extraction: Add 10 µL of Proteinase K to 400 µL of lysis buffer LB, mix well, and obtain DNA lysis buffer. Discard the cell culture supernatant and wash twice with PBS. Discard the PBS and add 410 µL of DNA lysis buffer. Let stand for 30 s, then pipette repeatedly 20 times to transfer the cell lysis buffer to a 1.5 EP tube. Incubate at 55 ℃ for 10 min, vortex to mix, and let stand at room temperature for 5 min. Remove the EP tube and allow it to cool to room temperature, then gently vortex to mix. Add 300 µL of protein removal buffer PL and 300 µL of binding buffer BD sequentially, and shake vigorously to mix. Centrifuge at 12000 rpm for 5 min. The solution will separate into two layers: the upper layer is a blue extraction layer, and the lower layer is a clear aqueous phase. There may be a partial precipitate layer between the two layers; the DNA is in the lower aqueous phase. Carefully aspirate the lower layer solution for column purification. Insert the DNA adsorption column T1 into a 2 mL collection tube for later use. Add 200 μL of buffer AC to DNA adsorption column T1, centrifuge at 12000 rpm for 1 min, and discard the waste liquid. Add the lower layer solution of the above sample pretreatment to DNA adsorption column T1, centrifuge at 12000 rpm for 1 min, and discard the waste liquid. Place DNA adsorption column T1 back into the collection tube, add 500 µL of wash buffer W (add anhydrous ethanol as per the instructions before use), centrifuge at 12000 rpm for 30 s, and discard the waste liquid. Repeat the washing with wash buffer W once. Place DNA adsorption column T1 back into the collection tube, centrifuge the empty column at 12000 rpm at room temperature for 2 min to remove residual wash buffer W. Place DNA adsorption column T1 into a new 1.5 mL centrifuge tube, add 25 µL of elution buffer preheated to 65℃ to the center of the adsorption column, and incubate at room temperature for 2 min. Then centrifuge at 12000 rpm for 1 min. Collect the filtrate. Add 25 µL of fresh, preheated elution buffer (65°C) and repeat the elution once more to obtain approximately 50 µL of DNA solution. After determining the concentration and mass of the DNA solution using a nanodrop, store at -20°C for later use. Primer sequences F: AGGGTGATGGGAAGGGTGTT, R: ACTTGCCCGTATCCATCCAC were designed for LSDVORF72. Prepare the qPCR reaction system according to the amounts shown in Table 1, and detect the gene abundance of the samples according to the reaction procedure shown in Table 2.
[0049] Table 1: qPCR system
[0050]
[0051] Table 2: qPCR Procedure
[0052]
[0053] 1.6 TCID 50 experiment
[0054] Sample preparation is the same as for qPCR. TCID 50 Assay: Using growth medium, 2 × 10⁶ cells were inoculated into 96-well plates. 4 MDBK cell suspension (100 μL / well). Culture plates were incubated for 24 h (37℃, 5% CO2). Virus solution was serially diluted 10-fold with maintenance medium (DMEM containing 2% FBS), with 8 replicates per well. 100 μL of the diluted virus solution was added to each well to maintain cell culture for 5 days. Finally, the number of diseased wells was observed and counted under a microscope, and the TCID of the virus solution was calculated using the Reed-Muench method. 50 .
[0055] 1.7 Time of addition experiment
[0056] The process of viral infection of host cells can be divided into four stages in chronological order: the stage before viral contact with the cell; the stage where the virus binds to host receptors and attaches to the surface of the host cell; the stage where the virus enters the cell through endocytosis; and the replication stage after the virus enters the cell. To determine at which stage of LSDV infection of MDBK cells the drug exerts its antiviral effect, this embodiment treated cells or the virus with the drug during rLSDV infection of MDBK cells, and evaluated the viral replication level using the mCherry and Luciferase proteins expressed by the virus. Figure 9 The experimental design pattern diagram for Time of addition provided in the embodiments of the present invention is as follows:
[0057] Inoculate 2×10⁶ cells into 96-well plates 4 MDBK cell suspension (100 μL / well). Culture plates were incubated in an incubator for 24 h. Four experimental groups were established based on different drug treatment durations.
[0058] Group 1 (Neutralization Phase): To determine whether the drug has a neutralizing effect on the virus before contact with cells, the drug was diluted to a 2× drug concentration working solution using maintenance solution. 50 μL of the 2× drug concentration working solution was then mixed with an equal volume of 200 TCID50. 50 rLSDV hybrid obtains 200 TCID 50 The rLSDV working solution at 1× drug concentration was prepared and neutralized at 37℃ for 1 h. The incubated solution was then seeded into the cells and incubated with MDBK cells for 2 h. The solution was discarded, and the cells were washed twice with 1×PBS. After discarding all the solution, 200 μL of maintenance solution was added, and the cells were cultured for another 72 h.
[0059] Group 2 (Blocking Phase): To determine whether the drug competitively binds to host cell receptors during viral adsorption into cells, the drug was diluted to a 1× drug concentration working solution using maintenance buffer. 100 μL of the 1× drug concentration working solution was added to the cells and incubated at 37°C for 1 h. The liquid was discarded, and the cells were washed twice with 1×PBS. After discarding all liquid, a solution containing 200 TCID50 was added. 50 100 μL of rLSDV was incubated with MDBK cells for 2 h. The liquid was discarded, and the cells were washed twice with 1×PBS. After discarding the liquid, 200 μL of maintenance medium was added, and the cells were cultured for another 72 h.
[0060] Group 3 (Cell Entry Phase): To determine whether the drug could prevent viral entry into cells, the drug was diluted to a 2× drug concentration working solution using maintenance solution. 50 μL of the 2× drug concentration working solution was then mixed with an equal volume of 200 TCID50 solution. 50 rLSDV hybrid obtains 200 TCID 50 100 μL of the 1× working solution of rLSDV was seeded into MDBK cells and incubated for 2 h. The solution was then discarded, and the cells were washed twice with 1×PBS. After discarding all the solution, 200 μL of maintenance solution was added, and the cells were cultured for another 72 h.
[0061] Group 4 (Replication Phase): To determine whether the drug inhibits viral replication after the virus enters the host cell, the drug was diluted to a 1× drug concentration working solution using maintenance solution. After discarding the liquid, a solution containing 200 TCID32 was added. 50 100 μL of rLSDV was incubated with MDBK cells for 2 h, the liquid was discarded, and the cells were washed twice with 1×PBS. After discarding the liquid, 200 μL of the 1× drug concentration working solution was added, and the cells were incubated at 37℃ for another 72 h.
[0062] DMSO was used as a control group in all four groups. Samples were collected at 72 hpi to detect the activity of Luciferase produced by the virus.
[0063] 1.8 Observation of viral DNA / RNA synthesis using laser confocal microscopy
[0064] EdU is a thymidine deoxyribonucleoside analogue. During DNA synthesis, EdU can be incorporated into the newly synthesized DNA as a raw material. Through a subsequent click reaction, EdU is labeled by Alexa Fluor488, so the newly synthesized DNA will emit green fluorescence under a fluorescence microscope.
[0065] Press 1×10 6MDBK cells were seeded into 6 cm² cell culture dishes at a density of [number] cells / dish. After 24 h, cells were seeded with 0.1 MOI LSDV. A blank control group was set up. At 24 hpi, the cells were washed twice with PBS and then digested with trypsin. 5 μL of PBS was added to each well of a 24-well plate, and cell spreaders were evenly distributed into the 24-well plate. 5 × 10⁵ cells / well were added to the wells containing the cell spreaders. 4 Cells were cultured per well. After 12 h, a drug solution was prepared using cell maintenance medium (DMEM with 2% FBS) and the cells were treated with the prepared drug solution for 30 min. Then, an EdU labeling solution (a mixture of cell maintenance medium, drug, and EdU at a final concentration of 10 μM) was prepared, mixed well, and the original drug solution in the wells was replaced with the EdU labeling solution. Cells were cultured for another 60 min. After EdU labeling, the culture medium was removed, and 1 mL of 4% paraformaldehyde fixative was added, and the cells were fixed at room temperature for 15 min. The fixative was removed, and the cells were washed three times with 1 mL of PBS for 5 min each time. The PBS was removed, and the cells were incubated at room temperature for 15 min with 1 mL of permeabilization buffer (PBS containing 0.3% Triton X-100) in each well. The permeabilization buffer was removed, and the cells were washed twice with 1 mL of PBS for 5 min each time. The washing buffer was removed, and the cells were blocked with IFA blocking buffer (PBS with 3% BSA) at room temperature for 1 h. Discard the blocking buffer, do not wash, and incubate with LSDV rabbit polyclonal antibody (1:1000) at room temperature for 1 h, washing three times with PBS for 5 min each time. Incubate with Alexa Fluor594-conjugated goat anti-mouse IgG (Thermo Fisher, USA) at room temperature for 1 h, washing three times with PBS for 5 min each time. Prepare the click reaction working solution according to the following system: 860 μL Click Reaction Buffer, 40 μL CuSO4, 2 μL Azide488, and 100 μL Click Additive Solution, for a total volume of 1 mL. Add 100 μL of the click reaction working solution to the wells of a 24-well plate. Incubate at room temperature in the dark for 30 min. Discard the click reaction working solution, wash three times with PBS, and finally add 100 μL of 1× Hoechst33342 solution to each well and incubate at room temperature in the dark for 10 min to label the total DNA. Remove the 1× Hoechst33342 solution, wash three times with PBS for 5 min each time, and then observe the fluorescence using a confocal microscope (Nikon A1 plus, Japan).
[0066] Similar to the principle of EdU labeling DNA, EU is a uracil nucleoside analogue. During RNA synthesis, EU can be incorporated into the newly synthesized RNA as a raw material. Through a subsequent click reaction, EU is labeled by Alexa Fluor488, resulting in green fluorescence under a fluorescence microscope. The experimental procedures for detecting the effect of the drug on LSDV RNA synthesis are basically the same as those for studying the drug's effect on DNA synthesis, except that the final concentration of EU used is 100 μM, unlike EdU.
[0067] 2. Experimental Results
[0068] 2.1 Drug CC 50 Measurement
[0069] To evaluate the in vitro cytotoxicity of the drug, we treated MDBK and Vero cells with different concentrations of the drug, measured cell viability using CCK-8 assays, and plotted cytotoxicity curves. Figure 2 and Figure 3 As shown, cytarabine in the MDBK cell line CC 50 The concentrations of iodoside, non-aluridine, and vidarabine in MDBK were 3.24 μM. 50 All were greater than 100 μM. The C6 concentrations of idioside, non-aluridine, cytarabine, and vidarabine in the Vero cell line were... 50 All are greater than 100 μM.
[0070] 2.2 Drug IC 50 Measurement
[0071] To evaluate the antiviral activity of the drugs in vitro, we treated MDBK and Vero cells with different concentrations of the drugs during rLSDV infection and used the mCherry protein expressed by the virus to mark viral proliferation in the cells. We plotted the inhibitory effects of the drugs on LSDV replication in the two cell lines by detecting the activity of virally expressed Luciferase. All four compounds showed dose-dependent effects on LSDV replication in both cell lines. Figure 2 and Figure 3 As shown, the IC50 of iodoside in the MDBK cell line 50 The IC50 of non-albuminuron in the MDBK cell line was 1.61 μM. 50 The IC50 of cytarabine in the MDBK cell line was 0.33 μM. 50 The IC50 of vidarabine at 0.14 μM in the MDBK cell line was [value missing]. 50 The IC50 value of idioside in Vero cell lines was 3.32 μM. 50 The IC50 value for non-aluridine in Vero cell lines was 12.68 μM.50 The IC50 of cytarabine in the Vero cell line was 3.17 μM. 50 The IC50 of vidarabine in Vero cell lines is less than 0.05 μM. 50 The value is 6.80 μM.
[0072] The Selectivity Index (SI) is an important indicator for evaluating the efficacy and safety of drugs. SI is defined as the compound selectivity (CC) of a drug. 50 With IC 50 The ratio, i.e., SI=CC 50 / IC 50 Selection index (SI) helps us understand at what concentration a drug can effectively inhibit pathogens while minimizing toxicity to host cells. Generally, a selection index greater than 1.00 is considered effective, and a higher selection index indicates a wider safety margin for the drug. 50 With IC 50 The ratio calculation results showed that the selection index of iodinated glycosides in the MDBK cell line was greater than 62.11, and the selection index of iodinated glycosides in the Vero cell line was greater than 7.89; the selection index of non-iodinated glycosides in the MDBK cell line was greater than 303.03, and the selection index of non-iodinated glycosides in the Vero cell line was greater than 31.55; the selection index of cytarabine in the MDBK cell line was greater than 714.29, and the selection index of cytarabine in the Vero cell line was greater than 2000; the selection index of vidarabine in the MDBK cell line was greater than 30.12, and the selection index of vidarabine in the Vero cell line was greater than 14.71. This indicates that iodinated glycosides, non-iodinated glycosides, cytarabine, and vidarabine have a wide safety range in inhibiting LSDV proliferation.
[0073] like Figure 4 , Figure 5 As shown, the higher the concentrations of idoxuridine, non-aluridine, cytarabine, and vidarabine used in MDBK and Vero, the lower the protein expression level of mCherry in rLSDV. This indicates that the inhibitory effects of idoxuridine, non-aluridine, cytarabine, and vidarabine on rLSDV proliferation in MDBK and Vero are dose-dependent.
[0074] 2.3 TCID 50 Verify drug efficacy
[0075] To evaluate the antiviral activity of the drug in vitro, we treated MDBK and Vero cells with 20 μM idoxuridine, 5 μM non-aluridine, 0.5 μM cytarabine, and 20 μM vidarabine, respectively, during LSDVXJ wild-type virus infection. The TCID of LSDV in the cell samples was detected at 72 hpi.50 The content was assessed to evaluate the drug's inhibitory effect on LSDV. For example... Figure 6 As shown, after treatment of the MDBK cell line with iodoside, non-iodoside, cytarabine, and vidarabine, the viral TCID in the cells was reduced. 50 The content decreased significantly (P<0.01, analyzed by independent samples t-test).
[0076] 2.4 qPCR validation of drug efficacy
[0077] To evaluate the antiviral activity of the drug in vitro, we treated MDBK and Vero cells with 20 μM idoxuridine, 5 μM non-aluridine, 0.5 μM cytarabine, and 20 μM vidarabine, respectively, during LSDVXJ wild-type virus infection. The inhibitory effect of the drug on LSDV was assessed by detecting the relative content of the LSDV gene in the cell samples at 72 hpi. Figure 7 As shown, after treatment of MDBK cell lines with iodoside, non-iodoside, cytarabine, and vidarabine, the relative expression level of the viral ORF72 gene in the cells was significantly reduced (P<0.01 according to independent samples t-test).
[0078] 2.5 Western blot analysis of drug efficacy
[0079] To evaluate the antiviral activity of the drug in vitro, we infected MDBK and Vero cells with LSDV at 0.01 MOI and 0.1 MOI, respectively. Cells were then treated with 20 μM idoxuridine, 5 μM non-aluridine, 0.5 μM cytarabine, and 20 μM vidarabine, respectively. Whole-cell lysates were collected at 72 hpi for Western blot analysis. Results are as follows: Figure 8 As shown, iodoside, non-iodoside, cytarabine, and vidarabine all exhibited good inhibitory effects on LSDV at different MOIs.
[0080] 2.6 Time of addition experiment: The compound mainly exerts its antiviral effect during the viral replication stage.
[0081] To determine at which stage of LSDV infection of MDBK cells the drug exerts its antiviral effect, we treated MDBK cells with 20 μM idoxuridine, 5 μM non-aluridine, 0.5 μM cytarabine, and 20 μM vidarabine during rLSDV infection. Viral replication levels were evaluated at 72 hpi by the expression of mCherry and Luciferase proteins. Figure 10 and Figure 11As shown, iodoside, non-iodoside, cytarabine, and vidarabine significantly inhibited LSDV replication during the viral replication phase (P<0.01, analyzed by independent samples t-test).
[0082] 2.7 Laser confocal microscopy observation: Compound inhibits LSDV DNA synthesis
[0083] DNA replication is a necessary biological process after LSDV enters the cell. To determine whether compounds affect DNA synthesis during viral replication, we treated MDBK cells with 20 μM idoxuridine, 5 μM non-aluridine, 0.5 μM cytarabine, and 20 μM vidarabine, respectively, during LSDV infection. Simultaneously, EdU was used to label newly synthesized viral and host DNA within 1 hour. Figure 12 As shown, iodoside, non-iodoside, cytarabine, and vidarabine can inhibit DNA synthesis during the LSDV replication phase.
Claims
1. The use of nucleotide analogs in the preparation of medicaments for the prevention and / or treatment of diseases caused by bovine nodular dermatosis virus, characterized in that, The nucleotide analogue is selected from any one or more of idoxuridine, non-aluridine, and cytarabine; the bovine nodular dermatitis virus (BNDV)-induced disease is bovine nodular dermatitis caused by BNDV; the concentration of idoxuridine used in the drug is 20 μM, the concentration of non-aluridine is 5 μM, and the concentration of cytarabine is 0.5 μM; the drug is a drug that inhibits the replication stage of BNDV; the drug uses any one or more of idoxuridine, non-aluridine, and cytarabine as its active ingredient.
2. The application according to claim 1, characterized in that, The drug also includes one or more pharmaceutically acceptable carriers.
3. The application according to claim 1, characterized in that, Pharmaceutically acceptable carriers include: binders, wetting agents, disintegrants, diluents, and / or surfactants.
4. The application according to claim 1, characterized in that, The dosage form of the drug is any one or more of tablets, capsules, oral liquids, granules, pills, or injections.
Citation Information
Patent Citations
Application of benserazide hydrochloride in preparation of medicine for treating diseases caused by respiratory syncytial virus
CN115919823A
North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses
US20090221523A1
